PTO-1542
(4-85)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ONLINE SEARCH REQUEST FORM

94178

USER Elli Pesckin SERIAL NUMBER 09/675,323

ART UNIT 1623 PHONE 308-4616 DATE 5/15/2003 mej
CM1 8B19

Please give a detailed statement of requirements. Describe as specifically as possible the subject matter to be searched. Define any terms that may have special meaning. Give examples or relevant citations, authors, or keywords, if known.

You may include a copy of the broadest and or relevant claim(s).



useful to treat androgen responsive diseases.

Point of Contact
P. Sheppard
Telephone number: (703) 308-4499

STAFF USE ONLY

COMPLETED _____
SEARCHER _____
ONLINE TIME _____ TOTAL TIME _____
(in minutes)
NO. OF DATABASES _____

SYSTEMS
____ CAS ONLINE
____ DARC/QUESTEL
____ DIALOG
____ SDC
____ OTHER

09/675323

```
=> fil hcaplus
FILE 'HCAPLUS' ENTERED AT 11:21:58 ON 20 MAY 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 20 May 2003  VOL 138 ISS 21
FILE LAST UPDATED: 19 May 2003  (20030519/ED)

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.

=>
=>

=> d stat que
L3                STR
```




```
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  21

STEREO ATTRIBUTES: NONE
L5           156 SEA FILE=REGISTRY SSS FUL L3
L6               STR
```



NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 25

STEREO ATTRIBUTES: NONE
L7 7 SEA FILE=REGISTRY SUB=L5 SSS FUL L6
L8 7 SEA FILE=HCAPLUS ABB=ON PLU=ON L7

=>
=>

=> d ibib abs hitrn l8 1-7

L8 ANSWER 1 OF 7 HCAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2003:334866 HCAPLUS
TITLE: Cosmetic composition containing a DHEA derivative and a soothing agent
INVENTOR(S): Picard-Lesboueyries, Elisabeth; Burnier, Veronique
PATENT ASSIGNEE(S): L'oreal, Fr.
SOURCE: PCT Int. Appl., 36 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003035023	A1	20030501	WO 2002-FR3510	20021014

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,

NE, SN, TD, TG
FR 2831440 A1 20030502 FR 2001-13816 20011025
PRIORITY APPLN. INFO.: FR 2001-13816 A 20011025

AB The invention relates to a compn. contg., in a physiol.-acceptable medium, at least one DHEA deriv. and at least one agent that can inhibit at least one enzyme selected from among phospholipases A2, lipoxygenases and/or human prostaglandin synthetases. The invention also relates to the cosmetic use of said compn., particularly in order to soothe cutaneous disorders including sensitive skin, cutaneous discomfort, skin tightness, pruritus, cutaneous irritations, cutaneous swelling, redness of the skin and/or cutaneous heat sensations. The invention also relates to a soothing cosmetic treatment method comprising the topical application of one such compn. A lotion for sensitive skin contained Paeonia suffruticosa ext. 0.50, 3.beta.-acetoxy-7-keto-DHEA 0.01, propylene glycol 20.00, hydroxypropyl cellulose 3.50, and Et alc. q.s. 100.00%.

IT **250163-05-4**
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)
(cosmetic compn. contg. DHEA deriv. and soothing agent)

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 2 OF 7 HCAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2003:334636 HCAPLUS
TITLE: Methods and synthesis of compounds for the treatment of blood cell disorders and delayed adverse and unwanted effect of radiation exposure
INVENTOR(S): Ahlem, Clarence N.; Reading, Christopher; Frincke, James; Stickney, Dwight; Lardy, Henry A.; Marwah, Padma; Marwah, Ashok; Prendergast, Patrick T.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 198 pp., Cont.-in-part of U.S. Ser. No. 675,470.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 9
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003083231	A1	20030501	US 2002-87929	20020301
US 2003060425	A1	20030327	US 2001-820483	20010329
ZA 2001003845	A	20020513	ZA 2001-3845	20010511

PRIORITY APPLN. INFO.:
US 1998-109923P P 19981124
US 1998-109924P P 19981124
US 1998-110127P P 19981127
US 1998-112206P P 19981215
US 1999-124087P P 19990311
US 1999-126056P P 19990323
US 1999-137745P P 19990603
US 1999-140028P P 19990616
US 1999-145823P P 19990727
US 1999-414905 B2 19991008
US 1999-161453P P 19991025
US 1999-449004 B2 19991124
US 1999-449042 B2 19991124
US 1999-449184 B2 19991124
US 1999-461026 B2 19991215
US 2000-535675 A2 20000323
US 2000-586672 B2 20000601
US 2000-586673 B2 20000601
US 2000-675470 A2 20000928
US 2001-272624P P 20010301

US 2001-820483 A2 20010329
US 2001-323016P P 20010910
US 2001-328738P P 20011011
US 2001-338015P P 20011108
US 2001-340045P P 20011130
US 2001-343523P P 20011220
US 2000-257071P P 20001220

AB The invention relates to the use of compds. to treat a no. of conditions, such as blood cell disorders and symptoms and conditions assocd. with delayed adverse or unwanted effects of radiation therapy. Compds. that can be used in the invention include methyl-2,3,4-trihydroxy-1-O-(7,17-dioxoandrost-5-ene-3.beta.-yl)-.beta.-D-glucopyranosiduronate, 16.alpha.,3.alpha.-dihydroxy-5.alpha.-androstan-17-one or 3,7,16,17-tetrahydroxyandrost-5-ene, 3,7,16,17-tetrahydroxyandrost-4-ene,3,7,16,17-tetrahydroxyandrost-1-ene or 3,7,16,17-tetrahydroxyandrostane that can be used in the treatment method. Methods for the synthesis of those compds. are exemplified. Formulation and dosage of those compds. are claimed.

IT **250163-05-4P 357923-34-3P 357923-35-4P**
357923-38-7P 357923-39-8P 515159-71-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(methods and synthesis of compds. for treatment of blood cell disorders and delayed adverse and unwanted effect of radiation exposure)

L8 ANSWER 3 OF 7 HCAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2002:963688 HCAPLUS
DOCUMENT NUMBER: 138:28973
TITLE: Cosmetic preparations containing new derivatives of 7-oxo-DHEA
INVENTOR(S): Dalko, Maria; Cavezza, Alexandre; Picard-Lesboueyries, Elisabeth; Renault, Beatrice; Burnier, Veronique
PATENT ASSIGNEE(S): L'oreal, Fr.
SOURCE: Eur. Pat. Appl., 32 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1266649	A1	20021218	EP 2002-291404	20020606
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
FR 2826011	A1	20021220	FR 2001-7804	20010614
JP 2003026697	A2	20030129	JP 2002-173449	20020613
US 2003054021	A1	20030320	US 2002-170679	20020614

PRIORITY APPLN. INFO.: FR 2001-7804 A 20010614
OTHER SOURCE(S): MARPAT 138:28973

AB Cosmetic prepns. contg. new derivs. of 7-oxo-DHEA (I) for improving the appearance of keratinic materials or prevention or treatment of skin aging, skin pigmentations, hyperseborrhea, and hair loss are claimed. Synthesis of I and cosmetic prepns. contg. I are disclosed.

IT **250163-05-4**
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)
(cosmetic prepns. contg. new derivs. of 7-oxo-DHEA)

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 4 OF 7 HCAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2002:695788 HCAPLUS

DOCUMENT NUMBER: 137:226941
TITLE: Use of certain steroids for treatment of a number of conditions including blood cell deficiencies
INVENTOR(S): Ahlem, Clarence N.; Reading, Christopher; Frincke, James; Stickney, Dwight; Lardy, Henry; Marwah, Padma; Marwah, Ashok; Prendergast, Patrick T.
PATENT ASSIGNEE(S): Hollis-Eden Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 383 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 9
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002069977	A1	20020912	WO 2002-US6708	20020301
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003060425	A1	20030327	US 2001-820483	20010329

PRIORITY APPLN. INFO.:

US 2001-272624P	P	20010301
US 2001-820483	A	20010329
US 2001-323016P	P	20010910
US 2001-328738P	P	20011011
US 2001-340054P	P	20011101
US 2001-338015P	P	20011108
US 2001-343523P	P	20011220
US 1998-109923P	P	19981124
US 1998-109924P	P	19981124
US 1998-110127P	P	19981127
US 1998-112206P	P	19981215
US 1999-124087P	P	19990311
US 1999-126056P	P	19990323
US 1999-137745P	P	19990603
US 1999-140028P	P	19990616
US 1999-145823P	P	19990727
US 1999-414905	B2	19991008
US 1999-161453P	P	19991025
US 1999-449004	B2	19991124
US 1999-449042	B2	19991124
US 1999-449184	B2	19991124
US 1999-461026	B2	19991215
US 2000-535675	A2	20000323
US 2000-586672	B2	20000601
US 2000-586673	B2	20000601
US 2000-675470	A2	20000928
US 2000-257071P	P	20001220

OTHER SOURCE(S): MARPAT 137:226941

AB The invention relates to the use of compds. to treat a no. of conditions, such as thrombocytopenia, neutropenia or the delayed effects of radiation therapy. Compds. that can be used in the invention include methyl-2,3,4-trihydroxy-1-O-(7,17-dioxoandrost-5-ene-3.beta.-yl)-.beta.-D-glucopyranosid ronate. Formulations contg. the steroids are also exemplified.

IT **250163-05-4P 357923-35-4P 357923-38-7P**
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic

preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(synthetic prepn. and use of certain steroids for treatment of a no. of conditions including blood cell deficiencies)

IT **250163-05-4DP**, salts, esters, ethers, amides, and prodrugs **357923-34-3DP**, salts, esters, ethers, amides, and prodrugs **357923-34-3P 357923-35-4DP**, salts, esters, ethers, amides, and prodrugs **357923-36-5DP**, salts, esters, ethers, amides, and prodrugs **357923-36-5P 357923-38-7DP**, salts, esters, ethers, amides, and prodrugs **357923-39-8DP**, salts, esters, ethers, amides, and prodrugs **357923-39-8P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(synthetic prepn. and use of certain steroids for treatment of a no. of conditions including blood cell deficiencies)

REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 5 OF 7 HCAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2001:293332 HCAPLUS
DOCUMENT NUMBER: 135:211172
TITLE: Ergosteroids IV: synthesis and biological activity of steroid glucuronosides, ethers, and alkylcarbonates
AUTHOR(S): Marwah, P.; Marwah, A.; Kneer, N.; Lardy, H.
CORPORATE SOURCE: Department of Biochemistry and Institute for Enzyme Research, University of Wisconsin-Madison, Madison, WI, USA
SOURCE: Steroids (2001), 66(7), 581-595
CODEN: STEDAM; ISSN: 0039-128X
PUBLISHER: Elsevier Science Inc.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 135:211172
GI



I

AB The 7-oxo deriv. of dehydroepiandrosterone is more active than the parent steroid and is devoid of adverse side effects in rats, monkeys and humans. In anticipation of possible therapeutic use we have sought more active, longer lasting forms of 7-oxo- and 7.beta.-hydroxydehydroepiandrosterones. The 7-oxo- and 7-hydroxy steroids have been converted to glucuronosides, ethers and carbonate esters. The syntheses of these compds. are described and their ability to induce the formation of liver thermogenic enzymes when fed to rats is reported. Some of the new derivs., e.g. I, were found to be somewhat more effective than the equimolar amts. of 7-oxo-DHEA with which they were compared in each expt.

IT **250163-05-4P 357923-35-4P 357923-38-7P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
(synthesis and biol. activity of steroid glucuronosides, ethers, and

alkylcarbonates)

IT **357923-34-3P 357923-36-5P 357923-39-8P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(synthesis and biol. activity of steroid glucuronosides, ethers, and alkylcarbonates)

REFERENCE COUNT: 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 6 OF 7 HCAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2001:247354 HCAPLUS
DOCUMENT NUMBER: 134:261560
TITLE: Therapeutic treatment of androgen receptor driven conditions using steroids or analogs
INVENTOR(S): Lardy, Henry A.; Marwah, Padma
PATENT ASSIGNEE(S): Hollis-Eden Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 88 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001023405	A2	20010405	WO 2000-US26848	20000928
WO 2001023405	A3	20020530		
W: AE, AG, AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EE, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2000077363	A5	20010430	AU 2000-77363	20000928
EP 1228083	A2	20020807	EP 2000-967114	20000928
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				

PRIORITY APPLN. INFO.:
US 1999-157275P P 19990930
US 1999-157347P P 19990930
US 1999-166116P P 19991116
WO 2000-US26848 W 20000928

OTHER SOURCE(S): MARPAT 134:261560

AB A method is claimed to treat or prevent an androgen responsive disease in a subject, or to ameliorate one or more symptoms thereof, comprising administering to a subject, or delivering to the subject's tissues, an effective amt. of a steroid or steroid analogs. The steroid is specifically an analog of 1,3,5(10)-estratriene-17.alpha.-ethynyl-3.beta.,17.beta.-diol; 17.alpha.-ethynylandrostene-3.beta.,17.beta.-diol; 3.beta.,17.beta.-dihydroxyandrost-5-en-16-one; or 3.beta.-methylcarbonate-androst-5-en-7,17-dione. The androgen responsive disease is prostate cancer, benign prostatic hyperplasia, breast cancer, alopecia, acne, hypogonadism or hirsutism. The method further comprises administering to the subject a second therapy; the second therapeutic agent is hydroxyflutamide, leuprolide, megesterol, diethylstilbesterol, aminoglutethimide, spironolactone, tamoxifen, cyproterone acetate, or bicalutamide.

IT **250163-05-4DP**, analogs
RL: BAC (Biological activity or effector, except adverse); BSU (Biological

study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(therapeutic treatment of androgen receptor driven conditions using steroids or analogs)
REFERENCE COUNT: 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 7 OF 7 HCAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1999:684497 HCAPLUS
DOCUMENT NUMBER: 131:332293
TITLE: Suppression of .DELTA.5-androstenediol-induced androgen receptor transactivation by selective steroids in human prostate cancer cells
AUTHOR(S): Chang, Hong-Chiang; Miyamoto, Hiroshi; Marwah, Padma; Lardy, Henry; Yeh, Shuyuan; Huang, Ko-En; Chang, Chawnshang
CORPORATE SOURCE: George Whipple Laboratory for Cancer Research, Departments of Pathology, Urology, Radiation Oncology, and the Cancer Center, University of Rochester Medical Center, Rochester, NY, 14642, USA
SOURCE: Proceedings of the National Academy of Sciences of the United States of America (1999), 96(20), 11173-11177
CODEN: PNASA6; ISSN: 0027-8424
PUBLISHER: National Academy of Sciences
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The authors' earlier report suggested that androst-5-ene-3.beta.,7.beta.-diol (.DELTA.5-androstenediol or Adiol) is a natural hormone with androgenic activity and that two potent anti-androgens, hydroxyflutamide (Eulexin) and bicalutamide (Casodex), fail to block completely the Adiol-induced androgen receptor (AR) transactivation in prostate cancer cells. Here, the authors report the development of a reporter assay to screen several selective steroids with anti-Adiol activity. Among 22 derivs./metabolites of dehydroepiandrosterone, the authors found 4 steroids [no. 4, 1,3,5(10)-estratriene-17.alpha.-ethynyl-3,17.beta.-diol; no. 6, 17.alpha.-ethynyl-androstene-diol; no. 8, 3.beta.,17.beta.-dihydroxy-androst-5-ene-16-one; and no. 10, 3.beta.-methylcarbonate-androst-5-ene-7,17-dione] that have no androgenic activity and could also block the Adiol-induced AR transactivation in prostate cancer PC-3 cells. Interestingly, these compds., in combination with hydroxyflutamide, further suppressed the Adiol-induced AR transactivation. Reporter assays further showed that these four anti-Adiol steroids have relatively lower glucocorticoid, progesterone, and estrogenic activity. Together, these data suggest some selective steroids might have anti-Adiol activity, which may have potential clin. application in the battle against the androgen-dependent prostate cancer growth.
IT **250163-05-4**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(androstenediol-induced androgen receptor transactivation suppression by selective steroids in human prostate cancer cells)
REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=>
=>

=> fil caold
FILE 'CAOLD' ENTERED AT 11:22:13 ON 20 MAY 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907-1966
FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

This file supports REGistRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

=>
=> s l7
L9 0 L7

=> fil reg
FILE 'REGISTRY' ENTERED AT 11:22:27 ON 20 MAY 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 19 MAY 2003 HIGHEST RN 518003-32-2
DICTIONARY FILE UPDATES: 19 MAY 2003 HIGHEST RN 518003-32-2

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2003

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=>
=>

=> d ide can l7 tot

L7 ANSWER 1 OF 7 REGISTRY COPYRIGHT 2003 ACS
RN 515159-71-4 REGISTRY
CN Androst-5-ene-7,17-dione, 3-[[(1,1-dimethylethoxy)carbonyl]oxy]-, (3.beta.)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C24 H34 O5
SR CA
LC STN Files: CAPLUS

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CAPLUS (1957 TO DATE)

L7 ANSWER 2 OF 7 REGISTRY COPYRIGHT 2003 ACS
RN 357923-39-8 REGISTRY
CN Androst-5-ene-7,17-dione, 3-[[(9H-fluoren-9-ylmethoxy)carbonyl]oxy]-, (3.beta.)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C34 H36 O5
SR CA
LC STN Files: CA, CAPLUS, CASREACT, TOXCENTER

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1957 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
3 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 137:226941

REFERENCE 2: 135:211172

L7 ANSWER 3 OF 7 REGISTRY COPYRIGHT 2003 ACS
RN 357923-38-7 REGISTRY
CN Androst-5-ene-7,17-dione, 3-[[(octyloxy)carbonyl]oxy]-, (3.beta.)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C28 H42 O5
SR CA
LC STN Files: CA, CAPLUS, CASREACT, TOXCENTER

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1957 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
3 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 137:226941

REFERENCE 2: 135:211172

L7 ANSWER 4 OF 7 REGISTRY COPYRIGHT 2003 ACS
RN 357923-36-5 REGISTRY
CN Androst-5-ene-7,17-dione, 3-[[(2-methylpropoxy)carbonyl]oxy]-, (3.beta.)-(9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C24 H34 O5
SR CA
LC STN Files: CA, CAPLUS, CASREACT, TOXCENTER

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1957 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
2 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 137:226941

REFERENCE 2: 135:211172

L7 ANSWER 5 OF 7 REGISTRY COPYRIGHT 2003 ACS
RN 357923-35-4 REGISTRY
CN Androst-5-ene-7,17-dione, 3-[(ethoxycarbonyl)oxy]-, (3.beta.)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH

MF C22 H30 O5
SR CA
LC STN Files: CA, CAPLUS, CASREACT, TOXCENTER

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1957 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
3 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 137:226941

REFERENCE 2: 135:211172

L7 ANSWER 6 OF 7 REGISTRY COPYRIGHT 2003 ACS
RN 357923-34-3 REGISTRY
CN Androst-5-ene-7,17-dione, 3-[[(2-propenyloxy)carbonyl]oxy]-, (3.beta.)-(9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C23 H30 O5
SR CA
LC STN Files: CA, CAPLUS, CASREACT, TOXCENTER

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1957 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
3 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 137:226941

REFERENCE 2: 135:211172

L7 ANSWER 7 OF 7 REGISTRY COPYRIGHT 2003 ACS
RN 250163-05-4 REGISTRY
CN Androst-5-ene-7,17-dione, 3-[(methoxycarbonyl)oxy]-, (3.beta.)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C21 H28 O5
SR CA
LC STN Files: CA, CAPLUS, CASREACT, TOXCENTER, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

5 REFERENCES IN FILE CA (1957 TO DATE)
2 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
7 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 138:28973

REFERENCE 2: 137:226941

REFERENCE 3: 135:211172

REFERENCE 4: 134:261560

REFERENCE 5: 131:332293

```
=> fil hcaplus
FILE 'HCAPLUS' ENTERED AT 11:24:57 ON 20 MAY 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 20 May 2003  VOL 138 ISS 21
FILE LAST UPDATED: 19 May 2003  (20030519/ED)

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.


=>
=>

=> d stat que l15 nos
L3                STR
L5            156 SEA FILE=REGISTRY SSS FUL L3
L6                STR
L7              7 SEA FILE=REGISTRY SUB=L5 SSS FUL L6
L8              7 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L7
L10           149 SEA FILE=REGISTRY ABB=ON  PLU=ON  L5 NOT L7
L11           252 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L10
L14             9 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L11(L)(?PHARM? OR ?MEDIC? OR
                  ?THERAP? OR ?DRUG? OR ?DISEAS? OR ?DISORDER?)
L15             8 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L14 NOT L8


=>
=>

=> d ibib abs hitrn l15 1-8

L15  ANSWER 1 OF 8  HCAPLUS  COPYRIGHT 2003 ACS
ACCESSION NUMBER:         2003:223737  HCAPLUS
DOCUMENT NUMBER:          138:215740
TITLE:                    7-Hydroxyl and 7-ketone derivatives of
                          3-.beta.-hydroxyl steroid hormones for the treatment
                          of inflammatory or functional diseases of the
                          intestine
INVENTOR(S):              Seman, Michel; Criton, Marc
PATENT ASSIGNEE(S):       Laboratoires Mayoly Spindler, Fr.
SOURCE:                   Fr. Demande, 19 pp.
                          CODEN: FRXXBL
DOCUMENT TYPE:            Patent
LANGUAGE:                 French
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.       KIND  DATE          APPLICATION NO.  DATE
```

FR 2829697	A1	20030321	FR 2001-11904	20010914
WO 2003024460	A1	20030327	WO 2002-FR3109	20020912

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: FR 2001-11904 A 20010914
OTHER SOURCE(S): MARPAT 138:215740

AB Use of 7-hydroxylated and 7-ketonic derivs. of the 3.beta.-hydroxylated hormones steroids for the prepn. of a medicament intended to treat the inflammatory or functional diseases intestine like Crohn's disease, hemorrhagic colitis and the irritable bowel syndrome.

IT **566-19-8**, 3.beta.-Hydroxy-5-androstene-7,17-dione
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(3-.beta.-hydroxylated steroid hormones derivs. for the treatment of inflammatory or functional **diseases** of the intestine)

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2002:240572 HCAPLUS
DOCUMENT NUMBER: 136:257756
TITLE: Treatment of inflammatory bowel disease by the administration of .DELTA.5-androstene-3.beta.-ol-7,17 dione and metabolizable precursors thereof
INVENTOR(S): Zenk, Ronald J.; Zenk, John L.
PATENT ASSIGNEE(S): Humanetics Corporation, USA
SOURCE: PCT Int. Appl., 10 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002024205	A1	20020328	WO 2001-US28895	20010918

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2001090989	A5	20020402	AU 2001-90989	20010918

PRIORITY APPLN. INFO.: US 2000-665640 A 20000919
WO 2001-US28895 W 20010918

AB Inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease, can be treated by the administration of .DELTA.5-androstene-3.beta.-ol-7,17 dione and metabolizable precursors thereof.

IT **566-19-8 1449-61-2**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)
(treatment of inflammatory bowel **disease** by the administration of .DELTA.5-androstene-3.beta.-ol-7,17 dione and metabolizable precursors)
REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 3 OF 8 HCAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2000:820640 HCAPLUS
DOCUMENT NUMBER: 134:95631
TITLE: Safety and pharmacokinetic study with escalating doses of 3-acetyl-7-oxo-dehydroepiandrosterone in healthy male volunteers
AUTHOR(S): Davidson, Michael; Marwah, Ashok; Sawchuk, Ronald J.; Maki, Kevin; Marwah, Padma; Weeks, Charles; Lardy, Henry
CORPORATE SOURCE: Chicago Center for Clinical Research, Chicago, IL, USA
SOURCE: Clinical and Investigative Medicine (2000), 23(5), 300-310
CODEN: CNVMDL; ISSN: 0147-958X
PUBLISHER: Canadian Medical Association
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Studies were carried out to evaluate the safety and pharmacokinetics of 3-acetyl-7-oxo-DHEA (3.beta.-acetoxyandrost-5-ene-7,17-dione) given orally. The study consisted of a randomized, double blind, placebo-controlled, escalating dose study in the Chicago Center for Clin. Research involving 22 healthy men. The participants received placebo or 3-acetyl-7-oxo-DHEA at 50 mg/d for 7 days followed by a 7-day washout; 100 mg/d for 7 days followed by a 7-day washout; and 200 mg/d for 28 days. Safety parameters, evaluated at each dose level, included measurement of total testosterone, free testosterone, dihydrotestosterone, estradiol, cortisol, thyroxine and insulin levels. Analyses for 7-oxo-DHEA-3.beta.-sulfate (DHEA-S), the only detectable metabolic product of the administered steroid, were conducted on plasma drawn from all subjects at 0.25, 0.5, 1, 2, 4, 6 and 12 h after the final 100 mg dose of 3.beta.-acetyl-7-oxo-DHEA. There were no differences in the clin. lab. values or in reported minor adverse experiences, between treatment and placebo groups. In general, blood hormone concns. were unaffected by the treatment with 3.beta.-acetyl-7-oxo-DHEA and remained within the normal range. No changes in vital signs, blood chem. or urinalysis occurred during treatment with 3.beta.-acetyl-7-oxo-DHEA compared to placebo. The administered steroid was not detected in the blood but was rapidly converted to 7-oxo-DHEA-S, the concns. of which were proportional to dose. This steroid sulfate did not accumulate; plasma concns. 12 h after the 3.beta.-acetyl-7-oxo-DHEA dose at 7 and 28 days on the 200 mg/d dose were 15.8 and 16.3 .mu.g/L resp. The mean time to peak plasma level of 7-oxo-DHEA-S was 2.2 h; the mean half life was 2.17 h. The apparent clearance averaged 172 L/h, and the apparent mean vol. of distribution was 540 L. These results indicate that 3.beta.-acetyl-7-oxo-DHEA is safe and well tolerated in normal healthy men at doses up to 200 mg/d for 4 wk.
IT **1449-61-2**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(dehydroepiandrosterone acetyloxo derive safety and **pharmacokinetics** and metab. and endocrine effects in men)
IT **4121-96-4**
RL: BPR (Biological process); BSU (Biological study, unclassified); MFM (Metabolic formation); BIOL (Biological study); FORM (Formation, nonpreparative); PROC (Process)
(dehydroepiandrosterone acetyloxo derive safety and **pharmacokinetics** and metab. and endocrine effects in men)

REFERENCE COUNT: 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 4 OF 8 HCAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2000:444298 HCAPLUS
DOCUMENT NUMBER: 133:203125
TITLE: 7-Hydroxydehydroepiandrosterone - a natural antiglucocorticoid and a candidate for steroid replacement therapy?
AUTHOR(S): Hampl, R.; Lapcik, O.; Hill, M.; Klak, J.; Kasal, A.; Novacek, A.; Sterzl, I.; Sterzl, J.; Starka, L.
CORPORATE SOURCE: Institute of Endocrinology, Prague, Czech Rep.
SOURCE: Physiological Research (Prague) (2000), 49(Suppl. 1), S107-S112
CODEN: PHRSEJ; ISSN: 0862-8408
PUBLISHER: Institute of Physiology, Academy of Sciences of the Czech Republic
DOCUMENT TYPE: Journal
LANGUAGE: English
AB 7-Hydroxylated metabolites of dehydroepiandrosterone (DHEA) are believed to be responsible for at least some immunomodulatory and antiglucocorticoid effects of DHEA and hence are considered candidates for hormone replacement therapy. Our expts. in vitro brought the evidence that 3.beta.,7.beta.-dihydroxy-5-androsten-3-one (7.beta.-OH-DHEA), but not DHEA and its 7.alpha.-hydroxyisomer, could counteract the immunosuppressive effect of dexamethasone on the formation of plaques in culture of murine spleen lymphocytes. In another expt., DHEA and after a 3-wk pause 3.beta.-hydroxy-5-androstene-7,17-dione (7-oxo-DHEA) were applied transdermally to 6 male volunteers on 5 consecutive days. Blood levels of DHEA, its 7-hydroxylated metabolites, and in the first case also dehydroepiandrosterone sulfate (DHEAS), were measured before, during and one day after the end of treatment. Application of DHEA increased significantly not only DHEA and DHEAS, but also its both 7-hydroxyisomers. Application of 7-oxo-DHEA also led to a significant increase of both 7-hydroxyisomers of DHEA, with 7.beta.-OH-DHEA being the preferred metabolite the concn. of which was increased more than three times.
IT **566-19-8**, 3.beta.-Hydroxy-5-androstene-7,17-dione
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(7-hydroxydehydroepiandrosterone, a natural antiglucocorticoid and possible candidate for steroid replacement **therapy**)
REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 5 OF 8 HCAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1994:208596 HCAPLUS
DOCUMENT NUMBER: 120:208596
TITLE: Treatment of Alzheimer's disease and modulation of immune system with .DELTA.5-androstenes
INVENTOR(S): Lardy, Henry A.
PATENT ASSIGNEE(S): Humanetics Corp., USA
SOURCE: PCT Int. Appl., 25 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 6
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9403176	A1	19940217	WO 1993-US7327	19930802

W: AT, AU, BB, BG, BR, CA, CH, CZ, DE, DK, ES, FI, GB, HU, JP, KP,

KR, KZ, LK, LU, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

US 5292730	A	19940308	US 1992-922850	19920731
AU 9349970	A1	19940303	AU 1993-49970	19930802
JP 08505602	T2	19960618	JP 1993-505536	19930802
JP 2762315	B2	19980604		
EP 746322	A1	19961211	EP 1993-919879	19930802
EP 746322	B1	20000119		

R: BE, DE, ES, FR, GB, IT, NL, SE

PRIORITY APPLN. INFO.:	US 1992-922850	A	19920731
	US 1990-575156	B1	19900829
	US 1992-867288	A2	19920410
	WO 1993-US7327	W	19930802

AB Alzheimer's disease and immune deficiency disorders may be effectively treated by administering a therapeutic amt. of a .DELTA.5-androstene-3.beta.-ol-17-one having a C7 substituent selected from the group consisting of oxo, hydroxy and groups convertible thereto by hydrolysis. 7-Oxo DHEA (I) was prepd. from DHEA acetate and tested in mice. I did not induce clin. apparent toxicity. I enhanced the immune response to an influenza virus when the normal response in mice was less than optimal.

IT **1449-61-2P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and reaction of, in prepn. of androsteneolone for treating Alzheimer's **disease** and modulating immune system)

IT **566-19-8P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of and Alzheimer's **disease** treatment and immune system modulation with)

L15 ANSWER 6 OF 8 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER:	1989:199311 HCAPLUS
DOCUMENT NUMBER:	110:199311
TITLE:	Quantitative thin-layer chromatographic analysis of dehydroepiandrosterone enanthate and estradiol valerate in pharmaceutical preparations and blood
AUTHOR(S):	Amin, M.
CORPORATE SOURCE:	Fac. Pharm., Al Azhar Univ., Cairo, Egypt
SOURCE:	Pharmazeutische Industrie (1989), 51(1), 109-12 CODEN: PHINAN; ISSN: 0031-711X
DOCUMENT TYPE:	Journal
LANGUAGE:	English

AB A simultaneous direct, quant., TLC-densitometric method for detn. of dehydroepiandrosterone enanthate (I) and estradiol valerate (II) in tablets, oily solns., and in blood is described. TLC was carried out on pre-coated silica gel 60 F254 gel plates and the spots were measured directly by the reflection method following development with 2,4-dinitrophenylhydrazine at 550 and 510 nm, for I and II, resp. The method is characterized by a short anal. time and good sensitivity, selectivity, and accuracy, and is therefore suitable for quality control, stability investigations, and pharmacokinetics studies. The relative std. deviation is 3.7% for I and 2.9% for II. A degrdn. product of I, 3.beta.-heptanoyloxy-5-androstene-7,17-dione, may also be detd. by this method.

IT **53926-88-8**
RL: ANT (Analyte); ANST (Analytical study)
(detn. of, in blood plasma and **pharmaceuticals** by TLC-densitometry)

L15 ANSWER 7 OF 8 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER:	1979:568998 HCAPLUS

DOCUMENT NUMBER: 91:168998
TITLE: Effect of chorionic gonadotropin on the urinary excretion of testosterone and other androgens in healthy males and in males with coronary atherosclerosis
AUTHOR(S): Marenich, L. P.
CORPORATE SOURCE: Sverdl. Med. Inst., Sverdlovsk, USSR
SOURCE: Kardiologiya (1979), 19(6), 76-9
CODEN: KARDA2; ISSN: 0022-9040
DOCUMENT TYPE: Journal
LANGUAGE: Russian
AB Chorionic gonadotropin [9002-61-3] (3000 units/day) injected i.m. for 3 days into normal men increased urinary excretion of testosterone [58-22-0], epitestosterone [481-30-1], androstenedione [63-05-8], and 7-keto-dehydroepiandrosterone [**566-19-8**]. In patients with ischemic heart **disease** this stimulatory effect of chorionic gonadotropin was generally much reduced. Thus, male patients with ischemic heart **disease** can also have decreased testis function.

L15 ANSWER 8 OF 8 HCAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1961:94761 HCAPLUS
DOCUMENT NUMBER: 55:94761
ORIGINAL REFERENCE NO.: 55:17871f-g
TITLE: Isolation of 5-androstene-7,17-dione-3.beta.-ol sulfuric ester from peripheral blood plasma and adrenal venous plasma
AUTHOR(S): Baulieu, E. E.; Emiliozzi, R.; Corpechot, C.
CORPORATE SOURCE: Fac. med., Paris
SOURCE: Experientia (1961), 17, 110-11
DOCUMENT TYPE: Journal
LANGUAGE: French
AB 5-Androstene-7,17-dione-3.beta.-ol sulfuric ester was isolated from the peripheral venous blood plasma of several virilized women, in adrenal venous plasma of one of them, and also in 3 cases of adrenal tumor.
IT **4121-96-4**, Androst-5-ene-7,17-dione, 3.beta.-hydroxy-, hydrogen sulfate
(in blood plasma in adrenal **disorder**)

=>
=>

=> select hit rn l15 1-8
E1 THROUGH E4 ASSIGNED

=>
=>

=> fil reg
FILE 'REGISTRY' ENTERED AT 11:25:17 ON 20 MAY 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 19 MAY 2003 HIGHEST RN 518003-32-2
DICTIONARY FILE UPDATES: 19 MAY 2003 HIGHEST RN 518003-32-2

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2003

Please note that search-term pricing does apply when

conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=>
=>

=> s e1-e4
1 566-19-8/BI
(566-19-8/RN)
1 1449-61-2/BI
(1449-61-2/RN)
1 4121-96-4/BI
(4121-96-4/RN)
1 53926-88-8/BI
(53926-88-8/RN)
L16 4 (566-19-8/BI OR 1449-61-2/BI OR 4121-96-4/BI OR 53926-88-8/BI)

=>
=>

=> d ide can l15 1-4
YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS' - CONTINUE? (Y)/N:end

=> d ide can l16 1-4

L16 ANSWER 1 OF 4 REGISTRY COPYRIGHT 2003 ACS
RN **53926-88-8** REGISTRY
CN Androst-5-ene-7,17-dione, 3-[(1-oxoheptyl)oxy]-, (3.beta.)- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 3.beta.-Heptanoyloxy-5-androstene-7,17-dione
FS STEREOSEARCH
MF C26 H38 O4
LC STN Files: BEILSTEIN*, CA, CAPLUS, USPATFULL
(*File contains numerically searchable property data)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1957 TO DATE)
4 REFERENCES IN FILE CAPLUS (1957 TO DATE)

REFERENCE 1: 138:28973

REFERENCE 2: 110:199311

REFERENCE 3: 82:47693

L16 ANSWER 2 OF 4 REGISTRY COPYRIGHT 2003 ACS
RN **4121-96-4** REGISTRY
CN Androst-5-ene-7,17-dione, 3-(sulfooxy)-, (3.beta.)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Androst-5-ene-7,17-dione, 3.beta.-hydroxy-, hydrogen sulfate (6CI, 7CI, 8CI)
OTHER NAMES:
CN 7-Oxo-5,6-dehydroepiandrosterone sulfate
FS STEREOSEARCH
MF C19 H26 O6 S
CI COM
LC STN Files: BEILSTEIN*, CA, CAOLD, CAPLUS, USPATFULL
(*File contains numerically searchable property data)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

14 REFERENCES IN FILE CA (1957 TO DATE)
15 REFERENCES IN FILE CAPLUS (1957 TO DATE)
5 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 138:180934

REFERENCE 2: 138:28973

REFERENCE 3: 137:303980

REFERENCE 4: 136:304231

REFERENCE 5: 134:95631

REFERENCE 6: 130:276909

REFERENCE 7: 126:6438

REFERENCE 8: 125:41730

REFERENCE 9: 76:124618

REFERENCE 10: 65:58271

L16 ANSWER 3 OF 4 REGISTRY COPYRIGHT 2003 ACS
RN **1449-61-2** REGISTRY
CN Androst-5-ene-7,17-dione, 3-(acetyloxy)-, (3.beta.)- (9CI) (CA INDEX

NAME)
OTHER CA INDEX NAMES:
CN Androst-5-ene-7,17-dione, 3.beta.-hydroxy-, acetate (6CI, 7CI, 8CI)
OTHER NAMES:
CN 3.beta.-Acetoxy-5-androsten-7,17-dione
CN 3.beta.-Acetoxyandrost-5-ene-7,17-dione
CN 5-Androsten-3.beta.-ol-7,17-dione acetate
CN 7-Keto Naturalean
FS STEREOSEARCH
MF C21 H28 O4
LC STN Files: BEILSTEIN*, CA, CAOLD, CAPLUS, CASREACT, CHEMCATS, IFICDB, IFIPAT, IFIUDB, TOXCENTER, USPATFULL
(*File contains numerically searchable property data)

Absolute stereochemistry. Rotation (-).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

82 REFERENCES IN FILE CA (1957 TO DATE)
82 REFERENCES IN FILE CAPLUS (1957 TO DATE)
14 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 138:192855

REFERENCE 2: 138:158820

REFERENCE 3: 138:158560

REFERENCE 4: 138:158559

REFERENCE 5: 138:56127

REFERENCE 6: 138:44508

REFERENCE 7: 138:28973

REFERENCE 8: 137:389043

REFERENCE 9: 137:289381

REFERENCE 10: 137:169693

L16 ANSWER 4 OF 4 REGISTRY COPYRIGHT 2003 ACS
RN **566-19-8** REGISTRY
CN Androst-5-ene-7,17-dione, 3-hydroxy-, (3.beta.)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Androst-5-ene-7,17-dione, 3.beta.-hydroxy- (8CI)
OTHER NAMES:
CN 3.beta.-Hydroxy-5-androstene-7,17-dione
CN 5-Androsten-3.beta.-ol-7,17-dione

CN 7-Keto-DHEA
CN 7-Ketodehydroepiandrosterone
CN 7-Oxodehydroepiandrosterone
FS STEREOSEARCH
MF C19 H26 O3
LC STN Files: BEILSTEIN*, BIOSIS, CA, CAOLD, CAPLUS, CASREACT, CSCHEM, IFICDB, IFIPAT, IFIUDB, MEDLINE, TOXCENTER, USPAT2, USPATFULL
(*File contains numerically searchable property data)

Absolute stereochemistry. Rotation (-).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

130 REFERENCES IN FILE CA (1957 TO DATE)
8 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
133 REFERENCES IN FILE CAPLUS (1957 TO DATE)
2 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 138:248958

REFERENCE 2: 138:215740

REFERENCE 3: 138:192855

REFERENCE 4: 138:180934

REFERENCE 5: 138:158820

REFERENCE 6: 138:158560

REFERENCE 7: 138:158559

REFERENCE 8: 138:158558

REFERENCE 9: 138:44508

REFERENCE 10: 138:28973